05:01 AM EDT, 08/08/2024 (MT Newswires) -- Vertex Pharmaceuticals ( VRTX ) said late Wednesday it signed a reimbursement agreement with NHS England to give eligible patients access to the company's Casgevy therapy for the treatment of transfusion-dependent beta thalassemia.

The company said the deal comes as the National Institute for Health and Care Excellence, or NICE, issued a positive recommendation for the use of Casgevy.

Transfusion-dependent beta thalassemia is a life-threatening genetic disease that requires frequent blood transfusions.

Vertex said it continues to work with NICE and NHS England to give eligible sickle cell disease patients in England access to Casgevy "as soon as possible."

Price: 470.04, Change: +4.15, Percent Change: +0.89